Quantum computing is moving from research labs into a more commercial phase, but the listed-company evidence is extremely uneven. IonQ is already reporting meaningful revenue growth and broader commercial deployments. Pasqal now has public-market access and real customer contracts. Rigetti is shipping systems but still generates very little revenue relative to its losses. IBM has scale and a funded roadmap, but quantum is still a small part of a much larger business. The opportunity is real; the current economics are not yet uniform.
Quantum computing stocks have re-entered the market spotlight. Pasqal surged in its Nasdaq debut. IonQ is reporting triple-digit revenue growth and expanding across computing, networking and sensing. Rigetti is receiving U.S. government support while still operating at a substantial loss. IBM is committing more than $10 billion to its quantum roadmap. The key question is no longer whether quantum computing has technical promise. It is which companies are translating that promise into deployed systems, paying customers and durable revenue — and which are still mostly being valued on future milestones.
Why Quantum Stocks Are Back in Focus
The sector has three simultaneous catalysts. First, governments increasingly treat quantum computing, networking and sensing as strategic technologies. Second, companies are moving beyond cloud access into on-premises deployments and specialized commercial systems. Third, public-market enthusiasm is expanding after years in which quantum equities were dominated by highly speculative expectations.
Pasqal’s August 2026 Nasdaq debut is a useful marker. The company entered public markets with commercial customers, deployed systems and 2025 revenue, yet the stock still jumped sharply on its first trading day. That is exactly the kind of situation Market Radar is designed to examine: real progress can coexist with a valuation narrative that moves much faster than operating results.
The Quantum Market Has Four Different Layers
Deployed hardware
Quantum computers installed at customer, university or government sites provide stronger evidence than a prototype that remains internal.
Usage-driven revenue
Cloud access can broaden the user base, but revenue quality depends on sustained utilization rather than one-time research grants.
Strategic funding
National-security and research funding can reduce capital pressure, but grants should not be confused with customer demand.
Fault tolerance
The largest long-term market may depend on fault-tolerant machines, but most current listed-company economics still come from pre-fault-tolerant systems and services.
Which quantum stocks have the clearest evidence today?
Recognized revenue is scaling rapidly, commercial deployments are broadening and the customer mix is becoming more substantial.
Both have identifiable customers and systems in use, but current commercial scale remains much smaller than the long-term market narrative.
Rigetti has credible technology and funding but weak current economics; IBM has deep resources and a serious roadmap, but quantum remains immaterial to the overall company.
5 Listed Companies With Different Levels of Commercial Evidence
| Company | Commercial evidence | What is real today | Main risk |
|---|---|---|---|
| IonQ | $80.1M Q2 revenue; FY26 guide raised to $280–290M; commercial deployments expanding | Systems, cloud, networking, sensing and government customers | Heavy losses and valuation sensitivity despite revenue growth |
| Pasqal | €16.5M 2025 revenue; seven machines deployed; commercial contracts including Saudi Aramco | Neutral-atom systems with existing customer installations | Newly public, small revenue base and persistent industry error challenges |
| Rigetti | $5.1M Q2 revenue; on-premises systems and up to $100M U.S. government funding letter of intent | System deliveries and research deployments | Revenue remains tiny relative to operating losses |
| IBM | 340+ organizations in network; >$10B five-year quantum commitment; 2029 fault-tolerance target | Large installed ecosystem, cloud access and R&D scale | Quantum remains immaterial to IBM’s consolidated financials |
| D-Wave | Long-running commercial annealing systems and enterprise optimization use cases | Production-oriented annealing workloads and customer access | Different architecture and market than gate-model peers; long-term competitive positioning remains debated |
Not all quantum milestones deserve the same weight
Customer hardware, usage and recurring commercial relationships provide the strongest operating evidence.
Contracts and government awards matter, but execution still determines whether they become durable revenue.
Qubit counts, fidelity and fault-tolerance targets can validate technology without validating current economics.
1. IonQ: The Strongest Current Revenue Evidence
IonQ is the clearest example of quantum commercialization moving beyond a research-stage revenue base. The company reported Q2 2026 revenue of $80.1 million, up 287% year over year, and raised full-year guidance to $280 million to $290 million. Management said roughly 60% of quarterly revenue was commercial and that its business was broadening across international and multi-product customers.
The caveat is equally important. IonQ still reported a very large GAAP net loss and a substantial adjusted EBITDA loss. That means investors are paying for growth, strategic positioning and future platform economics rather than mature profitability.
2. Pasqal: Real Customers, Small Revenue, Fresh Public-Market Hype
Pasqal entered Nasdaq in late August after merging with a SPAC. Reuters reported that the company generated €16.5 million of revenue in 2025, had deployed seven quantum machines and had existing commercial contracts including Saudi Aramco. Those facts make Pasqal more tangible than a pre-revenue research story.
But the public-market reaction was far larger than the current revenue base. The stock surged on debut, showing how quickly quantum narratives can re-rate when a scarce new pure-play becomes investable. The commercial evidence is real; the valuation sensitivity is also real.
3. Rigetti: Deployment Progress Without Revenue Scale
Rigetti reported Q2 2026 revenue of $5.1 million against a $28.1 million operating loss. The company is delivering Novera systems, participating in a hybrid quantum-classical supercomputing project with HPE and Pittsburgh Supercomputing Center, and has a letter of intent with the U.S. Department of Commerce for up to $100 million of research funding.
That is meaningful validation of technical capability and strategic relevance. It is not yet evidence of a scaled commercial business. Rigetti therefore sits lower on the traction ladder than IonQ despite strong government and research relationships.
4. IBM: The Largest Funded Roadmap, But Quantum Is Not the Stock Thesis Yet
IBM offers a different exposure profile. It has announced more than $10 billion of quantum investment over five years and says more than 340 organizations are already part of its quantum client and partner network. In August 2026 it connected its first modular cryogenic systems as part of the engineering path toward its planned Starling fault-tolerant quantum computer in 2029.
IBM may have the deepest balance sheet and one of the most credible roadmaps in the sector, but quantum is still only a small part of a company dominated by software, infrastructure and consulting. That makes IBM lower-beta exposure to the theme rather than a pure quantum equity.
5. D-Wave: Commercial Use Exists, But the Architecture Is Different
D-Wave has spent years commercializing quantum annealing for optimization problems in scheduling, logistics, resource allocation and related workloads. Its customer base has included industrial, government and research organizations, giving it a longer commercial history than many gate-model startups.
The analytical challenge is that annealing is not directly equivalent to the gate-model systems pursued by IonQ, Rigetti, IBM and Pasqal. Investors should therefore avoid comparing companies only by “qubits” or by treating the entire sector as one homogeneous technology race.
What the Quantum Narrative Gets Right
- Commercial deployments are increasing across cloud, on-premises systems and government programs.
- Strategic funding is expanding as governments treat quantum as a national-security technology.
- IonQ has moved beyond the tiny revenue base that characterized earlier public quantum companies.
- IBM’s spending and engineering milestones show that large incumbents still view fault-tolerant quantum as a serious long-term computing platform.
- Pasqal’s listing expands the number of investable quantum architectures available to public-market investors.
What the Narrative Can Overstate
- Revenue growth is not profitability. Even the strongest pure-play revenue growth still comes with substantial losses.
- Government funding is not customer demand. Grants and strategic awards can accelerate R&D without proving commercial product-market fit.
- Qubit counts are not comparable across architectures. Fidelity, connectivity, error correction and workload fit matter more than headline counts.
- Fault tolerance is still a future milestone. Much of the sector’s largest promised value remains dependent on systems not yet commercially available.
- Scarcity can inflate valuations. Newly listed pure plays can attract capital faster than their revenue bases justify.
The quantum-computing theme has progressed far enough that investors can now compare actual commercial evidence rather than only scientific roadmaps. But the sector still spans very different stages of maturity.
IonQ currently has the strongest pure-play revenue evidence. Pasqal has real deployments and customers but a small revenue base and fresh-listing volatility. Rigetti has credible systems and government backing but limited commercial scale. IBM offers the deepest funded roadmap with low pure-play sensitivity. D-Wave has real enterprise use cases, but its annealing architecture should not be analyzed as if it were identical to gate-model competitors.
Sources
Investment disclosure: This article is for informational and research purposes only. It is not investment advice, a recommendation to buy or sell securities, or a price target.